169 results about "Enzyme binding" patented technology

The invention discloses an enzyme linked immunosorbent assay kit for detecting a plasticizer in edible oil and application of the enzyme linked immunosorbent assay kit, and belongs to the technical field of enzyme linked immunosorbent assay. The enzyme linked immunosorbent assay kit comprises an elisa plate coated with a plasticizer coupling antigen, a plasticizer standard substance, an enzyme conjugate working solution, a plasticizer specific antibody working solution, a purification tube, a purification reagent, a standard substance diluent, a sample diluent, a substrate solution, a stop solution and a 10 * concentrated washing solution. The standard substance diluent provided by the invention is used for diluting a plasticizer standard substance at different temperatures to obtain a plasticizer standard solution, and the obtained plasticizer standard solution has basically consistent inhibition ratio, so that the stability of the kit is remarkably enhanced; meanwhile, the standard diluent and other components in the kit have a synergistic effect, so that the enzyme linked immunosorbent assay kit has the advantages of good specificity, high sensitivity, good accuracy and high stability when being used for detecting the plasticizer in the edible oil; therefore, the enzyme linked immunosorbent assay kit has a good application prospect in the detection of the plasticizer in the edible oil.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

The invention relates to a UGT enzyme subtype substrate specificity prediction method and model. On the basis of a directional message passing neural network, graph structure characterization of a small molecule compound and features of specific protein binding sites of UGT enzyme are deeply fused, a bimodal prediction normal form of'molecule + protein binding sites' is designed, a deep learning model is constructed, conversion from compound center prediction to molecule-enzyme binding site comprehensive prediction is achieved, and the prediction accuracy is improved. And accurate classification prediction can be carried out on UGT enzyme substrates and non-substrates.

The invention discloses a glucose-responsive hydrogen sulfide release cascade nano-enzyme as well as a preparation method and application thereof. The cascaded nano-enzyme takes BSA as a growth template and a carrier, and FeS and Au nano-particles are loaded. The FeS-coated Au is synthesized by adopting a biomineralization method, so that the co-loading of FeS and Au is realized, and good biocompatibility is achieved. Meanwhile, by combining the peroxidase-like activity of FeS and the glucose oxidase-like activity of Au, glucose can be catalyzed in a cascade manner to generate toxic hydroxyl free radicals, and drug-resistant bacteria are efficiently killed. In addition, the FeS (at) Au cascade nano-enzyme has a hydrogen sulfide gas release function, and can promote vascular regeneration by up-regulating a hypoxia inducible factor-1 pathway. The cascade nano-enzyme responding to the hyperglycemia microenvironment is combined with a gas treatment mechanism, blood glucose can be effectively consumed, drug-resistant bacterium infection can be eliminated, revascularization can be promoted, and a new strategy is provided for treatment of diabetes wounds infected by drug-resistant bacteria and regeneration of skin tissues.

The present invention relates to the field of antibodies; the invention relates to a PB transposase monoclonal antibody, in particular to a PB transposase monoclonal antibody and a detection kit thereof. In particular, provided is a PB transposase binding molecule comprising an antibody targeting a PB transposase, or an antigen-binding fragment thereof, the antibody comprising any set of CDRs described herein. The detection kit provided by the invention is strong in detection specificity, high in sensitivity and good in stability.

The invention relates to the technical field of biological medicine, in particular to an mRNA vaccine based on a protein degradation technology. The mRNA vaccine comprises an mRNA system and a lipid nanoparticle. The mRNA system refers to two mRNAs which can respectively encode an antigen-docking module and a recognition module-E3 ubiquitin ligase binding domain, the E3 ubiquitin ligase binding domain recruits an E3 ubiquitin ligase complex, the antigen is ubiquitinated and degraded into a peptide fragment by utilizing specific binding between the recognition module and the docking module, the peptide fragment is recognized by an MHC-I complex, and the E3 ubiquitin ligase binding domain is used for identifying the MHC-I complex. Then, the body immunity is activated, and the anti-tumor effect is realized. Besides, the invention provides a universal mRNA vaccine, that is, theoretically, different diseases can be treated only by replacing antigens in an mRNA system, the research and development time of the vaccine is greatly shortened, the research and development cost is reduced, a new thought is provided for tumor treatment, and the mRNA vaccine has a huge application prospect.

A compound, or a stereoisomer, isotopomer, tautomer, or salt thereof having a structure of: A-L-B wherein A is a ligand that can covalently bioconjugate to an unnatural amino acid bearing a tetrazine or other reactive handle, incorporated into a protein; L is a linker covalently attaching A and B; and B is a ligand that can bind to a E3 ligase.

The invention relates to the technical field of biology, in particular to a method for stably improving the titer of horse radish peroxidase labeled streptavidin. According to the method provided by the invention, streptavidin with different histidine label lengths is designed, and then the streptavidin is coupled with horse radish peroxidase oxidized by sodium periodate, so that high-titer horse radish peroxidase labeled streptavidin can be obtained. The invention also discloses application of the enzyme-labeled conjugate in a magnetic particle platform streptavidin-biotin system, and experimental results prove that the method provided by the invention can be used for stably preparing the enzyme conjugate with high titer and low background, and is widely applied in the streptavidin-biotin system.

In certain aspects, the disclosure relates to a method of detecting the presence of a ribonucleic acid (RNA) molecule in a sample, e.g., a sample comprising lipid nanoparticles, the method comprising: (a) contacting the sample in vitro with an oligonucleotide that is complementary to the RNA molecule; wherein the oligonucleotide comprises an RNA region and a DNA region; and wherein a duplex comprising the RNA molecule and the oligonucleotide is formed if the RNA molecule is present in the sample; (b) contacting the sample with RNase H; wherein, when the RNA molecule is present in the sample, the RNase H binds to the duplex and cleaves the RNA molecule to produce at least two fragments of the RNA molecule; and (c) detecting the presence or absence of at least one of the fragments of the RNA molecule. In some embodiments, the RNA molecule is a guide RNA, e.g., a sgRNA. In some embodiments, the method can be used to confirm the identity of the RNA molecule in the sample. In certain aspects, the disclosure relates to methods of quantifying an RNA molecule in a sample.

We describe compositions of DNA donor molecules compatible with various gene insertion methods with major advantages for delivery, nuclear localization, and immune evasion. The modified DNA donor molecules are largely single stranded but contain short regions of double-strand DNA to reconstitute enzyme binding sites, and can be combined with other approaches to enhance donor recruitment into the nucleus.

The present invention relates to: (a) an active camptothecin derivative represented by Chemical Formula 1 designed to bind to a DDX5 protein and an E3 ligase; (b) a prodrug of an active camptothecin derivative designed to release the active camptothecin derivative (a) at a target site in vivo; or (c) a complex containing a ligand targeting DDX5 protein, wherein the active camptothecin derivative (a) or the FL118 compound of the chemical formula 2 is linked through a linking group, so that the capability of inhibiting I-type topoisomerase is inactivated. The active camptothecin derivative designed according to the invention can be combined with DDX5 protein in cells, and cell death can be induced through the decomposition of the DDX5 protein.

The invention discloses a gene editing method of lactic acid bacteria from activated sludge, and belongs to the technical field of gene engineering. The invention provides a lactobacillus plantarum gene editing system based on original bacteriophage recombinase combined with a cre-lox system, which is characterized in that a fusion linear double-stranded DNA (deoxyribonucleic acid) fragment containing upstream and downstream homologous arms of a target gene and a resistance gene with a lox site is transformed into lactobacillus plantarum for expressing the original bacteriophage recombinase; and genome editing is realized by a homologous recombination method. In addition, the resistance screening marker is recovered by inducing transient expression of Cre enzyme, so that subsequent continuous editing of other genes is facilitated.

The present invention provides an efficient method for producing circular DNA. This method for producing circular DNA includes: (1) preparing circular DNA that will serve as a template, said circular DNA including (i) a replication initiation sequence capable of binding to an enzyme that has a DnaA activity, and (ii) a gyrase binding sequence, and said circular DNA not including a DnaA box cluster at a different position from the replication initiation sequence; (2) forming a reaction mixture of the circular DNA prepared in (1) and a reaction liquid including a first enzyme group that catalyzes replication of the circular DNA, a second enzyme group that synthesizes two sister circular DNAs forming a catenane, and a third enzyme group that catalyzes a separation reaction of the two sister circular DNAs; and (3) incubating the reaction mixture formed in (2) at a temperature of 80°C or lower, thereby obtaining a reaction product that includes the circular DNA, which has been amplified.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The invention discloses a PROTAC chimera for targeted degradation of an ROR [gamma] t receptor and application of the PROTAC chimera, the structure of the chimera is RW-L-Re, Re is a ligand capable of being combined with E3 ubiquitin ligase, L is a linking group covalently combined with at least one Re and at least one RW, and Rw is a target protein ROR [gamma] t binding ligand and is selected from one of the following structures. A series of PROTAC chimeras capable of degrading an ROR gamma t receptor in a targeted manner are designed and synthesized for the first time, a ternary complex is formed mainly by combining a target protein ligand and an E3 ubiquitin ligase ligand with POI and E3 ligase respectively, and then the POI is labeled with a ubiquitination tag and is further degraded by proteasome. Experimental results prove that the PROTAC chimera designed by the invention has excellent ROR [gamma] t receptor degradation activity, and can be used for preparing related drugs for treating autoimmune diseases or tumors.

The invention discloses a method for detecting Escherichia coli in food by combining Fe3O4 (at) Mo-CDs nano-enzyme with an aptamer, according to the method, near-infrared light response molybdenum-doped carbon dot modified Fe3O4 (at) Mo-CDs nano-enzyme is synthesized through a hydrothermal method, the Fe3O4 (at) Mo-CDs nano-enzyme has excellent NIR enhanced peroxidase activity and magnetism, 3, 3 ', 5, 5'-tetramethyl benzidine is oxidized to generate blue oxidized TMB, and the activity and magnetism of the NIR enhanced peroxidase are improved. After the surface of the Fe3O4 (at) Mo-CDs nano-enzyme is functionalized with an escherichia coli nucleic acid aptamer, the POD-like activity of the Fe3O4 (at) Mo-CDs nano-enzyme is inhibited, when Escherichia coli exists, the Fe3O4 (at) Mo-CDs nano-enzyme can be selectively combined with E.coli, the POD-like activity of the nano-enzyme is further inhibited, when the Fe3O4 (at) Mo-CDs nano-enzyme is used for detecting the E.coli in samples such as fruit juice and cakes, the detection limit is as low as 0.767 CFU / mL, and the Fe3O4 (at) Mo-CDs nano-enzyme has relatively high reliability and accuracy and can be widely applied to detection of E.coli. According to the invention, magnetic targeting separation and visual detection of E.coli are realized.

To provide IRAK degraders and uses thereof.SOLUTION: The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM, a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders. Compounds of the present invention, and compositions thereof, are useful as degraders and / or inhibitors of one or more IRAK protein kinases. In some embodiments, a provided compound degrades and / or inhibits IRAK-1 / 2 / 3 / 4.SELECTED DRAWING: None

The invention provides a retrotransposase, which comprises a target DNA binding structural domain containing a zinc finger binding motif, a reverse transcriptase structural domain and an endonuclease structural domain, and can be used for reversely transcribing RNA (Ribonucleic Acid) into DNA. The amino acid sequence of the retrotransposase is shown as any one of SEQ ID No.1 to 6 or SEQ ID No.32 to 43 or SEQ ID No.68 to 71 or has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% and 99% identity with the amino acid sequence of any one of SEQ ID No.1 to 6 or SEQ ID No.32 to 43 or SEQ ID No.68 to 71. The invention also relates to a system for modifying DNA. The system comprises the retrotransposase provided by the invention or a nucleic acid encoding the retrotransposase provided by the invention; and a donor RNA or a nucleic acid encoding the donor RNA, the donor RNA comprising: a sequence that binds to the retrotransposase and a heterologous sequence.

The application discloses a PROTAC compound with RORgamma t receptor targeted degradation and purposes thereof, which is a compound with a structure shown in a general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. e is a ligand capable of combining with an E3 ubiquitin ligase; the L is a linking group covalently combining at least one R e and at least one R W ; the R w is a target protein RORgamma t binding ligand; the application is based on the target point of RORgamma t and the PROTAC technology, and a series of RORgamma t-PROTACs are designed and synthesized for the first time. The mechanism is that the target protein ligand and the E3 ubiquitin ligase ligand are combined with POI and E3 ligase respectively, so as to form a ternary complex of "POI-PROTAC-E3 ligase". Then, the POI is marked with a ubiquitination label, and is degraded by a proteasome. The advantages of RORgamma t-PROTACs mainly include targeting of "undruggable proteins", small dosage, low toxicity, and difficulty in drug resistance. W -L-R e (I)

A composition and its uses and additionally a kit are provided. The composition is a synthetic self-complementary oligonucleotide that has a double-stranded region and a loop, wherein the double-stranded region contains a binding sequence for PaqCI. Additionally, the oligonucleotide includes unligatable 3′ and 5′ ends that cannot be cleaved by PaqCI. This oligonucleotide composition has been combined with PaqCI or a variant of PaqCI Type IIS restriction endonuclease in a reaction mixture, where the reaction mixture includes PaqCI or variant that can further be combined with a ligase and optionally a deadenylase, crowding molecule such as PEG and / or a repair enzyme such as Endo MS. The kit includes the oligonucleotide and Type IIS restriction endonuclease in the same or different containers.

The present invention addresses the problem of providing a novel compound having a Cerebron E3 ligase binding ability. It is possible to provide a compound represented by formula (I) [in the formula, each symbol is as set forth in the description], formula (II) [in the formula, each symbol is as set forth in the description], formula (III) [in the formula, each symbol is as set forth in the description], or formula (IV) [in the formula, each symbol is as set forth in the description], or a pharmacologically acceptable salt thereof. # imgabs0 #

The present application relates to a kind of metal-organic framework mediated multi-enzyme nanoparticles and its application, especially the method for alpha-amylase detection. By detecting product absorbance, the quantitative detection of alpha-amylase activity is realized. According to the nature of MFM analog enzyme and its ability as natural enzyme carrier, Agl@MFM@Gox@MFM is prepared, compared with natural enzyme, the composite material has strong resistance, can successfully protect the activity of enzyme. Based on the cascade catalytic system of multi-enzyme nanoparticles Agl@MFM@Gox@MFM, a biosensor is first synthesized and established for detecting alpha-amylase, successfully combines chemical catalyst with natural enzyme, has wide detection linear range (5-500 U / L) while has excellent specificity to alpha-amylase. Benefited from the advantages of low cost, easy preparation and excellent stability, the colorimetric sensor has been successfully used to determine the activity of alpha-amylase in koji.

Provided is a bifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein the bifunctional compound is represented by Formula (I):wherein:ABM is an androgen receptor binding moiety;-L- is a linking moiety; andCLM is a cereblon E3 ubiquitin ligase binding moiety represented by Formula (II)-1:wherein one end of the -L- is covalently joined to Q3, Q4, Q5 or Q6; and the other end of the -L- is covalently joined to the ABM. Also provided are a pharmaceutical composition comprising the bifunctional compound and a method for treating an androgen receptor related disease by administering the bifunctional compound.

The present invention provides a polypeptide NR6 having a dual function of regulating the activity of DBH and DDC enzymes and its application, belonging to the technical field of functional polypeptides. The present invention provides a polypeptide NR6 for the research of interfering small peptides that can target lipopolysaccharide binding protein and dopamine β-hydroxylase and aromatic L-amino acid decarboxylase, which has not yet been seen, and has the function of promoting the activity of dopamine β-hydroxylase and aromatic L-amino acid decarboxylase, thereby promoting the release of dopamine, norepinephrine, epinephrine, serotonin and melatonin in the body, and has anti-inflammatory, anti-depressant, memory recovery, sleep improvement, mental recovery and other functions. In addition, NR6 and its series of small peptides can penetrate the blood-brain barrier and have the advantages of small molecular weight and high stability, which are conducive to commercial application.

Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the engineered bifunctional receptors are capable of targeted degradation of a target protein. Also described in several example embodiments herein are compositions, formulations, and cells that can include or generate the engineered bifunctional receptors and uses thereof.

The invention provides a retrotransposase, which comprises a target DNA binding structural domain containing a zinc finger binding motif, a reverse transcriptase structural domain and an endonuclease structural domain, and can be used for reversely transcribing RNA (Ribonucleic Acid) into DNA. The invention also relates to a system for modifying DNA. The system comprises the retrotransposase provided by the invention or a nucleic acid encoding the retrotransposase provided by the invention; and a donor RNA or a nucleic acid encoding the donor RNA, the donor RNA comprising: a sequence that binds to the retrotransposase and a heterologous sequence.

The present disclosure relates to compounds, compositions, and methods for treating diseases or conditions mediated by aberrant histone deacetylase 8 (HDAC8) activity. The compounds disclosed comprise HDAC8 Targeting Ligand TL moiety covalently linked to a Dergon moiety recruiting E3 ubiquitin ligase to HDAC8. In some embodiments, the degron may bind the E3 ligase which is von Rippel-Lindau (VHL) tumor suppressor.

Disclosed is a novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof. Uses of the novel piperidinedione compound of Formula 1 or a pharmaceutically acceptable salt thereof as an anti-tumor agent or an immunomodulatory for treatment of CRBN protein-mediated diseases are disclosed. Also the compound or salt thereof can be used an E3 ligase binder in a PROTAC compound comprising a protein of interest ligand, a linker and an E3 ligase binder. Therefore, a PROTAC compound or a pharmaceutically acceptable salt thereof wherein, as an E3 ligase binder, the compound or salt thereof 1 is connected to the linker is disclosed:

We describe compositions of DNA donor molecules compatible with various gene insertion methods with major advantages for delivery, nuclear localization, and immune evasion. The modified DNA donor molecules are largely single stranded but contain short regions of double-strand DNA to reconstitute enzyme binding sites, and can be combined with other approaches to enhance donor recruitment into the nucleus.

A compound of formula I or a stereoisomer, isotopic isomer, tautomer or pharmaceutically acceptable salt thereof: wherein a ligand that binds to Nef protein (NB) is covalently linked to a ligand that binds to E3 ligase cerebron (CB) via a linker (L).